Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival
- PMID: 18992012
- DOI: 10.1111/j.1440-1789.2008.00970.x
Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival
Abstract
The three leucine-rich repeats and immunoglobulin-like domains (LRIG) genes encode integral membrane proteins. Of these, LRIG1 negatively regulates growth factor signaling and is implicated as a tumor suppressor in certain malignancies. In astrocytic tumors, the subcellular distribution of LRIG proteins is associated with specific clinicopathological features and patient survival. The role of LRIG proteins in oligodendroglioma has not previously been studied. Here we used immunohistochemistry to analyze the expression of the LRIG proteins in 63 oligodendroglial tumors, and evaluated possible associations between LRIG protein expression and clinicopathological parameters. Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival. This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.
Similar articles
-
LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix.Acta Oncol. 2010 Aug;49(6):812-5. doi: 10.3109/0284186X.2010.492789. Acta Oncol. 2010. PMID: 20553099
-
Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.Acta Neuropathol. 2006 Mar;111(3):238-46. doi: 10.1007/s00401-006-0032-5. Epub 2006 Mar 11. Acta Neuropathol. 2006. PMID: 16532360
-
Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.Int J Oncol. 2013 Jan;42(1):247-52. doi: 10.3892/ijo.2012.1702. Epub 2012 Nov 16. Int J Oncol. 2013. PMID: 23165628
-
LRIG and cancer prognosis.Acta Oncol. 2014 Sep;53(9):1135-42. doi: 10.3109/0284186X.2014.953258. Epub 2014 Sep 2. Acta Oncol. 2014. PMID: 25180912 Free PMC article. Review.
-
LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers.Curr Cancer Drug Targets. 2017;17(1):3-16. doi: 10.2174/156800961701161202200445. Curr Cancer Drug Targets. 2017. PMID: 27628597 Review.
Cited by
-
The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.Neuro Oncol. 2013 Sep;15(9):1200-11. doi: 10.1093/neuonc/not054. Epub 2013 May 30. Neuro Oncol. 2013. PMID: 23723255 Free PMC article.
-
In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.PLoS Genet. 2013;9(9):e1003824. doi: 10.1371/journal.pgen.1003824. Epub 2013 Sep 26. PLoS Genet. 2013. PMID: 24086156 Free PMC article.
-
Lrig2-deficient mice are protected against PDGFB-induced glioma.PLoS One. 2013 Sep 4;8(9):e73635. doi: 10.1371/journal.pone.0073635. eCollection 2013. PLoS One. 2013. PMID: 24023893 Free PMC article.
-
Role and mechanism of action of LRIG1 in ovarian cancer cell line and VP16 drug-resistant cell line.Oncol Lett. 2017 Oct;14(4):4619-4624. doi: 10.3892/ol.2017.6730. Epub 2017 Aug 7. Oncol Lett. 2017. PMID: 28943962 Free PMC article.
-
LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.Br J Cancer. 2013 May 14;108(9):1765-70. doi: 10.1038/bjc.2013.138. Epub 2013 Apr 4. Br J Cancer. 2013. PMID: 23558895 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous